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TNF receptor type 2 transmits caspase-dependent apoptotic signals 
in fibroblast-like synoviocytes derived from rheumatoid arthritis
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ABSTRACT  Signals from tumor necrosis factor α (TNFα) are transduced through two 
types of receptors, tumor necrosis factor receptor type1 (TNFR1) and type2 (TNFR2), which 
commonly transduce activation signals for NF-κB, affecting cellular survival, growth, and 
inflammation. TNFR1 is ubiquitously expressed and mediates caspase-dependent apoptotic 
signals, whereas TNFR2 is selectively expressed on hematopoietic cells without transducing 
death signals. We detected TNFR2 transcription in fibroblast-like synoviocytes derived from 
rheumatoid arthritis (RA-FLS) at various levels, but usually much lower than those of TNFR1. 
To investigate the function of TNFR2 on RA-FLS in TNFα signaling, we established a stable 
transfectant overexpressing TNFR2 using the human RA-FLS cell line MH7A and stimulated 
it with 50 ng/ml TNFα, a concentration that usually induces apoptosis in parent MH7A cells. 
Since TNFR2 is known to transduce anti-apoptotic signals via NF-κB activation, we expected 
to observe a reduction in apoptotic cells. Contrary to our expectations, the ratio of apoptotic 
cells in TNFR2 transfectants was higher than that of mock stable transfectants used as a 
control. This enhanced sensitivity to apoptosis was not inhibited by the addition of either anti-
TNFR2 monoclonal antibody (mAb) 80M2, which blocks ligand passing, or antagonistic anti-
TNFR1 Ab, indicating that apoptosis was independent of TNFR1 signals. Furthermore, in the 
presence of antagonistic anti-TNFR1 Ab, the addition of agonistic anti-TNFR2 Ab induced 
apoptosis with a rapid decrease in TNF receptor-associated factor 2 (TRAF2) and cleavage of 
caspase-8 and -3. The observed apoptosis was sensitive to an inhibitor of pan-caspase, but not 
of receptor-interacting protein (RIP) 1. These data clearly indicate the presence of a caspase-
dependent, apoptotic signaling pathway downstream of TNFR2.
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INTRODUCTION
   Rheumatoid  ar thr i t i s  (RA) is  a  chronic 
autoimmune disease that is characterized by 
hyperplasia of the synovium leading to joint 
destruction. Inflammatory mediators are produced 
by macrophages, fibroblasts, and endothelial cells, 
and induce bone destruction via the activation of 
osteoclasts１，２）. The inflammatory cytokine tumor 
necrosis factor α (TNFα) plays a pivotal role in 
the pathophysiology of RA, as evidenced by the 
effectiveness of anti-TNFα therapy in suppressing 
disease activity and bone destruction3－5）. However, 
approximately 30% of RA patients do not respond 
to anti-TNFα biological reagents６）, and the 
molecular mechanisms for this unresponsiveness are 
still unknown. 
   TNFα binds to two types of receptors, p55 
type 1 receptor (TNFR1) and p75 type 2 receptor 
(TNFR2). TNFR1 expression is ubiquitous, but 
TNFR2 expression is limited to immune cells７－９）. 
TNFR1 has a death domain in the cytoplasmic tail, 
but TNFR2 does not. Binding of TNFα to TNFR1 
recruits TNFR-associated death domain (TRADD) 
to its death domain, and forms complexes that 
include TRADD, TNF receptor-associated factor 2 
(TRAF2), cellular inhibitor of apoptosis protein-1 
(cIAP1), and the serine/threonine kinase, receptor-
interacting protein (RIP) 1 (Complex I). TRAF2/
cIAP1-mediated ubiquitination of RIP1 activates 
IκB kinase (IKK). Active IKK phosphorylates IκB, 
leading to its proteasomal degradation, and then 
released NF-κB (p65 and p50) translocates to the 
nucleus and induces transcription of the target genes. 
RIP1 dissociated from Complex I associates with 
Fas-associated death domain protein (FADD) and 
caspase 8 to form Complex IIa, in which caspase 
8 is activated to initiate apoptosis10－12）. A novel 
type of cell death, necroptosis, is also mediated by 
TNFR1. In the absence of caspase activity, RIP1 
interacts with RIP3 to form Complex IIb, which 
induces necroptosis. TNFR2 lacks a death domain 
and stimulation of TNFR2 leads to the activation of 
NF-κB, but not to the induction of apoptosis. 
   We inferred that the aberration of TNFR structure 
or function might contribute to the unresponsiveness 
of some RA patients to anti-TNFα therapy. We 
examined TNFR mutations among primary RA-
FLSs because mutations in the trans-membrane 
region of TNFR1 cause continuous inflammation 
associated with TNF receptor-associated periodic 
syndrome (TRAPS)/ familial Hibernian fever13）. 
We did not detect any mutations, except for a single 
nucleotide polymorphism, A36G, which has been 
described previously14） and is silent, in one case of 
RA-FLS. Next, we examined the expression levels 
of both receptors and noticed that the transcription 
levels of TNFR2 vary among primary RA-FLSs. 
This prompted us to study the role of TNFR2 in 
RA-FLS, particular its role in the pathophysiology 
of RA. However, the properties of TNFR2 are still 
controversial. For instance, forced expression of 
TNFR2 in a cervical cancer cell line facilitates 
apoptosis induced by TNFα stimulation15）. TNFα 
induces expression of TNFR2 and promotes cell 
proliferation in a colorectal cancer cell line16）. 
Cellular responses mediated by TNFR2 appear to be 
cell-type dependent. 
   In this study, we revealed that TNFR2 lacking 
the death domain can transduce caspase-dependent 
apoptotic signals in the RA-FLS cell line MH7A 
with forced expression of TNFR2. 
MATERIALS AND METHODS
Cells and cell culture
   MH7A, an RA-FLS line transformed with 
SV40TAg, was obtained from the Riken Cell 
Bank (Ibaragi, Japan). Cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% heat-inactivated fetal 
calf serum with antibiotics in 10% CO2 at 37℃ 
with humidified air. Primary FLSs were described 
previously17） and the study protocol was approved 
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by the Research Ethics Committee of Kawasaki 
Medical School (#291-2). 
Antibodies
   FITC-conjugated mouse anti-human TNFR1 
monoclonal antibody (mAb) (clone H398, MBL, 
Nagoya, Japan) and PE-conjugated mouse anti-
human TNFR2 mAb (clone 80M2, MBL) were used 
for the detection of TNFR1 and TNFR2 in FACS 
analysis. Unlabeled mouse anti-human TNFR2 mAb 
80M2 was utilized to stabilize the binding between 
TNFα and TNFR2 (MBL). Antagonistic mouse 
anti-human TNFR1 mAb (MAB225, clone 16803, 
R&D Systems, Minneapolis, MN, USA) was used to 
neutralize TNFR1. Goat anti-TNFR2 Ab (AB226PB, 
R&D Systems) was used as agonistic antibody to 
stimulate TNFR2, as reported by Chan et al.18）. 
       
Establishment of a stable transfectant overexpressing 
TNFR2
   cDNA for Tnfr2 was obtained by RT-PCR with 
total RNA of MH7A and gene-specific primers for 
Tnfr2 (Forward, 5′-GGCCCTCGAGATGGCGCCC
GTCGCCGTCTGG-3′; Reverse, 5′-CGGGGATC
CTTAACTGGGCTTCATCCCAGC-3′) using high-
fidelity DNA polymerase (KOD-Plus-Neo; Toyobo, 
Osaka, Japan). The PCR product was inserted into 
the pBluescript II cloning vector (STRATAGENE, 
La Jolla, CA, USA) and the lack of mutations was 
confirmed by sequencing with T7 or T3 primers. 
The vector was replaced with the pEBMulti vector 
(Wako, Osaka, Japan), and the expression vector was 
transfected into MH7A using the liposome method 
(Xtreme Gene; Roche, Basel, Switzerland). After 
several passages in medium containing hygromycin, 
the cells were stained with PE-anti-TNFR2 Ab, and 
cells overexpressing TNFR2 were enriched by cell 
sorting with FACSAria (BD Biosciences, San Jose, 
CA, USA). The sorted cells were cultured in the 
medium to establish stable transfectants. 
Quantitative real-time PCR
   The total RNA was extracted with TRIzol 
(Invitrogen, Carlsbad, CA, USA), according to the 
manufacturer’s instructions. Random hexamer-
primed cDNAs were prepared using the ReverTra 
Ace RT Kit (Toyobo). Specific primers for each 
gene were designed using Universal Primer Design 
Tools available on the Roche website. Real-time 
PCR with the SYBR Green 1 dye was carried out 
using the 7300 Real-Time PCR System (PE Applied 
Biosystems, Carlsbad, CA, USA). Threshold cycle 
(Ct) values of the target genes were normalized to 
those of β-actin. 
Cell Proliferation assay
   One hundred thousand stable transfectants in 
1 ml of culture medium in a 12-well plate were 
pre-treated with either 2 μg/ml anti-TNFR2 Ab 
80M2 or the same concentration of mouse IgG1 
for 30 min, then cultured for an additional 72 h in 
the presence of TNFα at various concentrations 
(indicated in the Figs. 2A and 3A). At the end of 
the culture, the cell number was counted using a 
hemocytometer. 
Apoptosis assay
   Early and late apoptotic cells were stained with 
FITC-conjugated Annexin V (BioVision, Inc., 
Milpitas, CA, USA) and 7AAD, respectively, and 
were detected simultaneously with the FACSCalibur 
(BD Biosciences).  The early apoptotic cell 
population was defined as Annexin V+ 7AAD－ cells 
and the late apoptosis cell population was defined as 
Annexin V+ 7AAD+ cells in the FACS analysis. 
Western blot analysis
   Cell lysates were prepared in RIPA lysis 
buffer  wi th  equal  cel l  numbers  f rom each 
sample. The equivalent whole-cell crude lysates 
were resuspended in sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
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sample buffer, boiled for 5 min, resolved using 
SDS-PAGE, transferred electrically to a PVFD 
(polyvinylidene fluoride) membrane (Immun-Blot, 
Bio-Rad, Hercules, CA, USA), and subjected to 
a western blot analysis with a signal-enhancing 
kit obtained from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA, USA). The membrane was probed 
with rabbit polyclonal antibodies for TRAF2, 
and anti-Caspase3 or mouse anti-Caspase8 mAb 
(Cell Signaling Technology, Inc., Danvers, MA, 
USA). The bound antibodies were detected with 
HRP-labeled goat anti-rabbit or goat anti-mouse 
antibodies. 
RESULTS
Establishment of the transfectant R2H stably 
expressing TNFR2
   To analyze the properties of TNFR2 in RA-
FLS, we established an MH7A- derived stable 
transfectant, designated R2H, expressing TNFR2 
at a high level. RT-PCR analyses revealed that the 
difference in tnfr1 expression levels between R2H 
and parental MH7A (Parent) or mock transfectants 
(Mock) was only 2-fold. However, the tnfr2 
expression level in R2H was 4,720 times higher 
than that of mock transfectants. (Fig. 1A). FACS 
analyses revealed that the mean fluorescence 
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Fig. 1. The expression level of TNFR2 in stable transfectant R2H cells. 
A. The transcription of TNFR2 in R2H cells was evaluated by real-time PCR. Parent MH7A cells (Parent) and stable transfectants 
introduced with the expression vector only (Mock) were used as controls. Fold-changes in the expression level of either tnfr1 or 
tnfr2 were calculated by the ΔΔCT method, setting the parent value as “1.”
B. Surface expression of either TNFR1 or TNFR2 was analyzed on FACS with FITC-anti-TNFR1 and PE-anti-TNFR2 Abs, 
respectively. 
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intensity of R2H stained with anti-TNFR2 mAb 
increased, whereas that of mock transfectants 
showed no increase compared with the unstained 
control (Fig. 1B). The amount of surface expression 
of TNFR1 on R2H was similar to the levels on the 
mock transfectant and parental MH7A cells. We 
expected that the biological responses of RA-FLS to 
TNFα would be modified by the forced expression 
of TNFR2 in R2H. 
R2H is highly sensitive to TNFα  induced apoptosis
   TNFR2-mediated NF-κB activity was expected 
to have an anti-apoptotic effect; accordingly, we 
attempted to confirm this activity using R2H with 
TNFα treatment. Unexpectedly, the R2H cell 
number was dramatically reduced during a 24-h 
culture with a high dose of TNFα in comparison 
with mock cells (Fig. 2A). We examined whether 
this reduction in living cells was due to the 
induction of apoptosis by staining with Annexin 
V. The fraction of early apoptosis R2H cells was 
markedly increased after stimulation with TNFα 
(61.2% ±13.6) in comparison with that in the Mock 
cells (16.5% ±1.3) (Fig. 2B and 2C). Of note, even 
in the absence of TNFα, R2H showed an increased 
frequency of Annexin V-positive cells (13.8%±0.9) 
compared with the Mock cells (7.5%±1.9). 
 
Enhanced apoptosis of R2H by TNFα  stimulation 
was not due to   “ ligand passing” from TNFR2 to 
TNFR1
   In the ligand passing theory proposed by 
Goeddel18）, i) TNFα binds to TNFR2 first owing 
to its higher affinity to TNFα than TNFR1, ii) 
captured TNFα immediately dissociates from 
TNFR2 due to its high dissociation constant, and 
iii) released TNFα binds to proximal TNFR1. Thus, 
increased expression of TNFR2 may result in an 
increased amount of TNFα passing from TNFR2 to 
TNFR1, leading to an enhancement of the TNFR1-
mediated apoptotic signal. 
   The sensitivity of R2H to TNFα was examined 
in the presence of anti-TNFR2 Ab (80M2), which 
stabilizes the binding between TNFα and TNFR2, 
to inhibit the passing of TNFα to TNFR1. However, 
the addition of 80M2 did not influence the number 
of living cells (Fig. 3A) or cells in apoptosis (Fig. 
3B and 3C) after treatment with TNFα, suggesting 
that ligand passing is not involved in augmented 
TNFα -induced apoptosis of R2H and the apoptotic 
signal was transmitted via TNFR2. 
Stimulating anti-TNFR2 Ab can induce apoptosis of 
R2H
   To further confirm the possibility that TNFR2 
conducts apoptotic signals, the combination of 
blocking Ab for TNFR1 (MAB225) and stimulating 
Ab  fo r  TNFR2  (AB226PB)  was  adop ted . 
The inhibitory effect of MAB225 on NF-κB 
activation was evidenced by the reduction in the 
phosphorylation status of p65, an indicator of the 
signal transduction of TNFα via TNFR1 (Fig. 4A). 
   MAB225 alone failed to reduce the TNFα
-induced apoptosis of R2H, indicating that TNFR1 
signaling was not involved in this apoptotic pathway 
(Fig. 4B and 4C). The adaptor protein TRAF2 
plays a crucial role for TNFR signaling19）. Of note, 
the ubiquitin-dependent degradation of TRAF2 by 
cIAP1 occurs via the binding of TNFα to TNFR220）. 
This rapid degradation of TRAF2 was observed 
when R2H was treated with the combination of 
MAB225 and AB226PB, indicating this treatment 
actually stimulates TNFR2 (Fig. 4D). Finally, this 
combination of Abs more strongly induced Annexin 
V+ apoptotic cells for R2H (44.4%±20.6) than 
mock cells (11.3% ±3.8), revealing the existence of 
novel TNFR2-mediated apoptotic signals (Fig. 4E 
and 4F). 
TNFR2-mediated apoptotic pathway is caspase-
dependent
   Apoptotic signals are initiated by the binding of 
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Fig. 2. Growth retardation and enhanced cell death of R2H. 
A. Mock and R2H cells were plated at a density 1 × 105/well in a 12-well plate. The cells were cultured for 24 h in the presence 
or absence of TNFα at various concentrations indicated in the figure. Then, the cells were harvested and counted using a 
hemocytometer. Gray bars and white bars indicate Mock and R2H cells, respectively. A representative result is shown from three 
independent experiments. Results are presented as means±S.D. from the triplicate experiments. Differences between mock and 
R2H cells treated with TNFα marked with * and ** were statistically significant (*p < 0.05, **p < 0.01).
B. Mock or R2H cells were cultured for 24 h in the absence or presence of TNFα at a concentration of 50 ng/ml, and were 
stained with FITC-conjugated Annexin V and 7AAD. Apoptotic cells were defined as Annexin V+ cells in the FACS analysis. The 
numbers in the representative FACS profile indicate the sum of the frequencies of Annexin V+ 7AAD－and Annexin V+ 7AAD+ 
populations.
C. The percentage of Annexin V positive cells was shown as bar graphs. Gray bars and white bars indicate Mock and R2H cells, 
respectively. Results are presented as means±S.D. from three independent experiments including one indicated in B. Differences 
between mock and R2H cells treated with TNFα marked with * and ** were statistically significant (*p < 0.05, **p < 0.01). 
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Fig. 3. No effect of anti-TNFR2 Ab (80M2), which stabilizes the binding between TNFα and TNFR2, on TNFα-induced 
apoptosis of R2H. 
A. Transfectant cells were plated at 1 × 105 /well and pretreated with 2 μg/ml 80M2 for 30 min. The cells were cultured for 
an additional 24 h in the presence or absence of TNFα at various concentrations indicated in the figure. Then the cells were 
harvested and counted using a hemocytometer. Asterisks (*) indicate statistically significant differences (*p < 0.05), and NS 
means not significant.
B. Mock and R2H cells were cultured for 24 h in the absence or presence of TNFα at a concentration of 50 ng/ml, and were 
stained with FITC-conjugated Annexin V and 7AAD. Apoptotic cells were defined as Annexin V+ cells in the FACS analysis. The 
numbers in the representative FACS profile indicate the sum of Annexin V+ 7AAD－ and Annexin V+ 7AAD+ populations.
C. The percentage of Annexin V positive cells was shown as bar graphs. Results are presented as means±S.D. of four 
independent experiments. NS means not significant. 
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Fig. 4. No contribution of signals from TNFR1 to TNFα-induced apoptosis of R2H.
A. The activation status of NF-κB was measured by the intensity of PE-conjugated anti-phosphorylated p65 (RelA) on FACS. 
Dashed line: unstimulated, solid line: stimulated with TNFα at a concentration of 50 ng/ml for 5 min.
B. Mock and R2H cells, pretreated with 3 μg/ml neutralizing anti-TNFR1 Ab (MAB225) or isotype-matched control Ab for 30 
min, cultured for an additional 24 h in the presence of TNFα at a concentration of 50 ng/ml, and stained with FITC-conjugated 
Annexin V and 7AAD. Apoptotic cells were defined as Annexin V+ cells in the FACS analysis. The numbers in the representative 
FACS profile indicate the sum of the frequencies of Annexin V+ 7AAD－ and Annexin V+ 7AAD+ populations.
C. The percentage of Annexin V positive cells was shown as bar graphs. Gray bars and white bars indicate Mock and R2H cells, 
respectively. Results are presented as means±S.D. from five independent experiments. NS means not significant.
D. The kinetics of the amount of TRAF2 after selective stimulation through TNFR2. Mock and R2H cells were treated with 3 μg/
ml agonistic anti-TNFR2 Ab (AB226PB) for 30 min in the presence of neutralizing anti-TNFR1 Ab (MAB225) and evaluated at 
the indicated time points by a western blotting analysis (upper panel). The graph shows the relative amounts of TRAF2 protein 
quantified on a densitometer normalized with those of β-actin as an internal control (lower panel). Gray bars and white bars 
indicate Mock and R2H cells, respectively. Asterisks (**) indicates statistically significant difference (**p < 0.01).
E. Apoptosis assay was performed using 3 μg/ml agonistic anti-TNFR2 Ab (AB226PB) or isotype-matched control Ab instead 
of TNFα in B. The number in the representative FACS profile indicates the sum of the frequencies of Annexin V+ 7AAD－ and 
Annexin V+ 7AAD+ populations.
F. The percentage of Annexin V positive cells was shown as bar graphs. Gray bars and white bars indicate Mock and R2H 
cells, respectively. Results are presented as means±S.D. from six independent experiments. Asterisks (*) indicate statistically 
significant differences (*p < 0.05).
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TRADD-FADD complex to the death domain within 
the cytoplasmic portion of TNFR1. Subsequently 
the complex activates caspase-3 and -8, the direct 
effecter molecules for apoptosis. Since TNFR2 
lacks the death domain, it seemed unlikely that 
the TNFR2-mediated pathway utilizes caspases. 
Contrary to the expectation, cleaved-product of 
caspase 3 (17/19 kDa) was clearly detected in 
R2H at 2 h after stimulation with the combination 
of MAB225 and AB226PB, as shown in Fig. 5A. 
Cleaved-product of Caspase8 (43 kDa) was also 
detected under the same conditions (Fig. 5A). These 
data indicate that caspase-3 and -8 are involved in 
the TNFR2-mediatied apoptosis.
   Recent studies have demonstrated that not only 
caspase-dependent apoptosis pathways, but also 
RIP1/RIP3-dependent necroptosis pathways are 
mediated by TNFR121）. The pan-caspase inhibitor 
zVAD-FMK (zVAD) s ignificant ly  reduced 
the Annexin V+ cells of R2H induced by the 
combination of MAB225 and AB226PB (from 
43.3% ± 16.3 to 16.0% ± 5.3). However, the RIP1 
inhibitor necrostatin-1 (Nec-1)21，22） had no apparent 
effect on Annexin V+/7AAD+ dead cells of R2H 
(from 43.3% ± 16.3 to 40.4% ± 14.5), indicating 
caspase activation is required for the TNFR2-
mediated apoptosis pathway (Fig. 5B and 5C). 
DISCUSSION
   TNFα is thought to play a pivotal role in inducing 
hyperplasia of the RA synovium through NF-κB 
activation23）. The importance of NF-κB in inhibiting 
TNFR1-mediated apoptosis in human primary 
FLS is also evidenced by the dual knock-down of 
p65 and p50 subunits of NF-κB24）. TNFR2 lacks 
a death domain and stimulation of TNFR2 leads to 
activation of the RIP/IKK complex and NF-κB 
without involvement of the pro-apoptotic pathway. 
Thus, it is reasonable to think that TNFR2 signals 
have a cytoprotective effect25，26）. However, the 
cellular responses mediated by TNFR2 appear to be 
cell-type dependent. For instance, forced expression 
of TNFR2 in the cervical cancer cell line HeLa 
results in enhanced apoptosis by TNFα stimulation, 
although the molecular mechanism for this effect 
has not been elucidated. In the present study, we 
showed that TNFR2 signals have a cytocidal effect 
in the RA-FLS cell line. Furthermore, we clearly 
demonstrated that this cytocidal signal from TNFR2 
is caspase-dependent. 
   Thus, TRAF2 seems to inhibit caspase-8 activation 
by recruiting cIAP1  to the TNFR1  complex 
following TNFα stimulation20）. One mechanism that 
may account for TNFR2-mediated apoptosis signals 
is the rapid downregulation of TRAF2 found in R2H 
treated with stimulating Ab to TNFR2. In TNFR1-
mediated apoptosis signaling, TNFα binding to 
TNFR1 recruits FADD to the TNFR1 signaling 
complex, which promotes the recruitment of pro-
casapase-8 to FADD via the death domain. The 
oligomerized pro-casapase-8 on FADD is activated 
by auto-cleavage, and mature caspase-8 successively 
cleaves both pro-casapase-3 and pro-Bid, leading 
to their activation as pro-apoptotic molecules. 
Therefore, FADD is thought to be an indispensable 
platform for casapase-8 activation. Thus, in TNFR2-
mediated apoptosis, future studies are necessary to 
determine how caspase-8 is activated independent 
on FADD. If the molecules connecting TNFR2 to 
caspase-8 are identified, they are potential targets 
for manipulations to artificially induce apoptosis of 
proliferative RA-FLS. 
   Ban et al. revealed that agonistic stimulation of 
TNFR2 induces the apoptosis of auto-reactive T 
cells from diabetes patients27）. Future developments 
of the methods to activate cell surface proteins 
on specific target cells will facilitate the use of 
this strategy to treat auto-immune diseases, and 
might have applications for the elimination of pro-
inflammatory FLS in RA, as shown in this study.
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Fig. 5. Activation of Caspase-8 and -3 in R2H cells stimulated with agonistic anti-TNFR2 Ab.
A. Cleavages of Caspase-8 and -3 after treatment of Mock and R2H cells with 3 μg/ml of agonistic TNFR2 Ab (AB226PB) for 
30 min in the presence of neutralizing TNFR1 Ab (MAB225) were evaluated at the indicated time points by a western blotting 
analysis. Representative data from three independent experiments are shown.
B. Mock and R2H cells, pretreated with 50 μM zVAD or 100 μM Nec-1 for 60 min, were subsequently treated with 3 μg/ml 
neutralizing anti-TNFR1 Ab (MAB225) for 30 min. Those cells were cultured for an additional 24 h in the presence of 3 μg/ml 
agonistic anti-TNFR2 Ab (AB225PB), and stained with FITC-conjugated Annexin V and 7AAD. Apoptotic cells were defined 
as Annexin V+ cells in the FACS analysis. The numbers in the representative FACS profile indicate the sum of the frequencies of 
Annexin V+ 7AAD－ and Annexin V+ 7AAD+ populations.
C. The percentage of Annexin V positive cells was shown as bar graphs. Gray bars and white bars indicate Mock and R2H 
cells, respectively. Results are presented as means±S.D. from five independent experiments. Asterisks (*) indicate statistically 
significant differences (*p < 0.05), and NS means not significant. 
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䛆Erratum䛇
Fig. 4B in the manuscript (doi䠖10.11482/KMJ-E41䠄2䠅29; Kawasaki Medical Journal 41(2) 29-40, 
TNF receptor type 2 transmits caspase-dependent apoptotic signals in fibroblast-like synoviocytes
derived from rheumatoid arthritis. Hirano H, et al) had been changed.
